FDA approves Actemra subcutaneous injection for active systemic JIA
4 monthes ago - By Healio
The FDA has approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older, according to a press release from Genentech.
Often characterized by inflammation in one or more joints, and a daily, spiking fever for at least 2 weeks that is sometimes accompanied by a skin rash, systemic juvenile idiopathic arthritis is the rarest form of juvenile arthritis, affecting approximately 30,000 children in the United States. Prior studies have determined that other accompanying symptoms can include
Read more ...
The headlines of Master Doctor
Chemical Exposure During Pregnancy Could Lower Blood Pressure Levels
Exposure to chemicals such as phthalates, parabens or Bisphenol A can decrease blood pressure during pregnancy, reveals a new study.
These '10 Year Challenge' Climate Change Photos Are Absolutely Haunting
These before and after photos proving climate change is definitely happening are devastating The “10 year challenge” has been sweeping social media with people posting pics of...
Raising A Child With Strong Faith When You're Not So Sure
I was making dinner one night when my 3-year-old came up to me with a stack of papers in his hands. He hands me the papers and says “These are to teach you about Jesus. Share...
A National Survey on Interhospital Transport of Children in Cardiac Arrest*
Objectives: To describe the U.S. experience with interhospital transport of children in cardiac arrest undergoing cardiopulmonary resuscitation. Design: Self-administered...